Quantcast

Initial detection of circulating tumor cells from metastatic prostate cancer patients with a novel small device.

Research paper by Kotaro K Obayashi, Jun J Akatsuka, Yuki Y Endo, Hayato H Takeda, Tatsuro T Hayashi, Yuka Y Toyama, Yasutomo Y Suzuki, Tsutomu T Hamasaki, Go G Kimura, Takashi T Ohnaga, Yukihiro Y Kondo

Indexed on: 25 Jan '20Published on: 24 Jan '20Published in: Prostate International



Abstract

Various devices for isolating and detecting circulating tumor cells (CTCs) have been developed, whereas the CellSearch® system has been clinically used in numerous prostate CTC studies. CTCs might become more useful surrogate markers of prostate cancer, and they should be measured in all settings, but a smaller, low-cost CTC capture system is required. An inexpensive and highly sensitive microfluidic CTC-capture polymeric chip, developed by the Toyama Industrial Technology Center, as described in the following text, was used to assess the number of CTCs from patients with metastatic prostate cancer. After verifying that cultured human prostate cancer cells (PC3 and LNCaP) could be captured with the chip coated with anti-epithelial cell adhesion molecule (CD326) antibody, whole blood samples of 14 patients with prostate cancer were screened. The average capture efficacy of PC3 cells was 94.60% in phosphate-buffered saline (PBS) and 83.82% in whole blood. The average capture efficacy of LNCaP cells was 82.73% in PBS and 75.78% in whole blood. CTCs were detected by the chip device in all 14 patients with metastatic prostate cancer using 2-mL blood samples. Although fewer CTCs were detected in patients with oligometastases, all patients with multiple distant metastases had CTCs. The average CTC count was 48 cells/mL (range 1-81 cells/mL). This CTC-chip will be able to capture CTCs and be useful to check CTCs as a surrogate marker in prostate cancer with smaller samples and lower cost in any small institution. © 2019 Asian Pacific Prostate Society, Published by Elsevier Korea LLC.